跳至主要内容
临床试验/NCT06576427
NCT06576427
已完成
不适用

Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II

Jupiter Endovascular37 个研究点 分布在 4 个国家目标入组 123 人2024年10月15日

概览

阶段
不适用
干预措施
Vertex Pulmonary Embolectomy System
疾病 / 适应症
Pulmonary Embolism
发起方
Jupiter Endovascular
入组人数
123
试验地点
37
主要终点
Reduction in Right ventricle (RV) / Left Ventricle (LV) ratio
状态
已完成
最后更新
26天前

概览

简要总结

This study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of acute pulmonary embolism.

详细描述

The study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of acute pulmonary embolism. The Vertex Pulmonary Embolectomy System is intended for the non-surgical removal of emboli and thrombi from blood vessels as a means for treating pulmonary embolism.

注册库
clinicaltrials.gov
开始日期
2024年10月15日
结束日期
2026年3月3日
最后更新
26天前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

发起方
Jupiter Endovascular
责任方
Sponsor

入排标准

入选标准

  • . Age ≥ 18 years \< 80 years
  • Acute onset of symptoms \< 14 days consistent with the presence of pulmonary embolism.
  • CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
  • RV/LV ratio of \> 0.9 on CTA as assessed by investigator (site determined).
  • Systolic blood pressure ≥ 90 mmHg (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with fluids)
  • Subject or subject's legally authorized representative (LAR) - applicable for US is willing and able to provide written informed consent prior to receiving any non-standard of care Clinical Investigation Plan-specific procedures
  • Subject is willing and able to comply with all Clinical Investigation Plan required follow-up visits

排除标准

  • Thrombolytic use within 30 days of baseline CTA
  • Pulmonary hypertension with peak pulmonary artery pressure \> 70 mmHg by right heart catheterization (site determined)
  • Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg
  • Unstable heart rate \> 130 beats per minute prior to procedure
  • FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90%
  • Hematocrit \< 28%
  • Platelets \< 100,000/μL
  • Serum baseline creatinine \> 1.8 mg/dL
  • International normalized ratio (INR) \> 3
  • Major trauma injury severity score (ISS) \> 15 within the past 14 days

研究组 & 干预措施

Vertex Pulmonary Embolectomy System

Patients presenting with clinical signs and symptoms of acute PE and who meet the study criteria will be treated with the Vertex Pulmonary Embolectomy System

干预措施: Vertex Pulmonary Embolectomy System

结局指标

主要结局

Reduction in Right ventricle (RV) / Left Ventricle (LV) ratio

时间窗: From baseline to 48 hours or discharge

Reduction in RV/LV ratio from baseline to 48 hours or discharge by (core lab assessed) CT angiography

Major Adverse Events, a composite of:

时间窗: Within 48 hours of the procedure

Device-related death within 48 hours of the procedure Major bleeding within 48 hours of the procedure Device-related AEs within 48 hours, including: * Clinical deterioration * Pulmonary vascular injury * Cardiac injury

研究点 (37)

Loading locations...

相似试验

相关资讯